YS Biopharma (YS) to Release Earnings on Friday

YS Biopharma (NASDAQ:YS) is set to post its quarterly earnings results before the market opens on Friday, April 19th.

YS Biopharma (NASDAQ:YS) last announced its quarterly earnings data on Monday, January 22nd. The company reported ($0.16) EPS for the quarter. The business had revenue of $13.64 million for the quarter. On average, analysts expect YS Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

YS Biopharma Trading Up 9.6 %

Shares of YS traded up $0.08 during midday trading on Wednesday, reaching $0.94. The stock had a trading volume of 413,726 shares, compared to its average volume of 199,102. The company’s fifty day simple moving average is $0.61 and its two-hundred day simple moving average is $0.57. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.09. YS Biopharma has a 1-year low of $0.35 and a 1-year high of $2.37.

Institutional Investors Weigh In On YS Biopharma

Several hedge funds and other institutional investors have recently made changes to their positions in the business. XTX Topco Ltd purchased a new stake in YS Biopharma in the 2nd quarter valued at $31,000. Barclays PLC acquired a new position in shares of YS Biopharma in the second quarter valued at approximately $150,000. Finally, FMR LLC purchased a new stake in shares of YS Biopharma during the first quarter worth approximately $1,864,000. Institutional investors and hedge funds own 52.64% of the company’s stock.

YS Biopharma Company Profile

YS Biopharma Co, Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.